ALTH Allos Therapeutics, Inc. (MM)

WESTMINSTER, Colo., June 25 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced that it was selected to join the broad-market Russell 3000(R) Index. This inclusion was effective at the close of trading on June 22, 2007, when the Russell Investment Group reconstituted its set of U.S. and global equity indexes. Annual reconstitution of Russell's U.S. indexes captures the 3,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. The largest 1,000 companies in this ranking comprise the Russell 1000(R) Index and the next largest 2,000 companies become the Russell 2000(R) Index. The Russell 3000(R) Index serves as the U.S. component of the Russell Global(R) Index. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. According to the Russell Investment Group, an industry-leading $4 trillion in assets currently are benchmarked to Russell indexes. About Allos Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent for which the Company expects to initiate a Phase 1 study in patients with advanced solid tumors in the second half of 2007. For additional information, please visit the Company's website at http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Derek Cole, Vice President, Investor Relations, +1-720-540-5367, ; or Jennifer Neiman, Senior Manager, Corporate Communications, +1-720-540-5227, , both of Allos Therapeutics, Inc. Web site: http://www.allos.com/

Copyright